Neuroprotective Effect of Protease-Activated Receptor-2 in the Hypoxia-Induced Apoptosis of Rat RGC-5 Cells

[1]  P. Walter,et al.  Early hyperbaric oxygen treatment for nonarteritic central retinal artery obstruction. , 2012, American journal of ophthalmology.

[2]  Ying Sun,et al.  The down regulation of neutrophil oxidative metabolism by S100A8 and S100A9: implication of the protease-activated receptor-2. , 2012, Molecular immunology.

[3]  Dorota L. Stankowska,et al.  Neuroprotection in Glaucoma , 2011 .

[4]  G. Reiser,et al.  Phosphorylation of Ser45 and Ser59 of αB‐crystallin and p38/extracellular regulated kinase activity determine αB‐crystallin‐mediated protection of rat brain astrocytes from C2‐ceramide‐ and staurosporine‐induced cell death , 2011, Journal of neurochemistry.

[5]  M. Hollenberg,et al.  Structure, function and pathophysiology of protease activated receptors. , 2011, Pharmacology & therapeutics.

[6]  Ying Wu,et al.  Activation of PAR2 or/and TLR4 promotes SW620 cell proliferation and migration via phosphorylation of ERK1/2. , 2011, Oncology reports.

[7]  M. D. den Bakker,et al.  Cardiovascular , Pulmonary and Renal Pathology Protease-Activated Receptor-2 Induces Myofibroblast Differentiation and Tissue Factor Up-Regulation during Bleomycin-Induced Lung Injury Potential Role in Pulmonary Fibrosis , 2010 .

[8]  T. Bushell,et al.  Astrocytic activation and an inhibition of MAP kinases are required for proteinase‐activated receptor‐2‐mediated protection from neurotoxicity , 2010, Journal of neurochemistry.

[9]  G. Reiser,et al.  αA‐crystallin and αB‐crystallin, newly identified interaction proteins of protease‐activated receptor‐2, rescue astrocytes from C2‐ceramide‐ and staurosporine‐induced cell death , 2009, Journal of neurochemistry.

[10]  J. Crowston,et al.  Recharacterization of the RGC-5 retinal ganglion cell line. , 2009, Investigative ophthalmology & visual science.

[11]  E. Ling,et al.  Hypoxia-ischemia and retinal ganglion cell damage , 2008, Clinical ophthalmology.

[12]  Dov Weinberger,et al.  Molecular and histological changes following central retinal artery occlusion in a mouse model. , 2008, Experimental eye research.

[13]  M. Steinhoff,et al.  Proteinase-activated receptor-2 in the skin: receptor expression, activation and function during health and disease. , 2008, Drug News and Perspectives.

[14]  T. Luger,et al.  Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. , 2008, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[15]  G. Reiser,et al.  Protease-activated receptors in the brain: Receptor expression, activation, and functions in neurodegeneration and neuroprotection , 2007, Brain Research Reviews.

[16]  G. Reiser,et al.  Activation of protease‐activated receptors in astrocytes evokes a novel neuroprotective pathway through release of chemokines of the growth‐regulated oncogene/cytokine‐induced neutrophil chemoattractant family , 2007, The European journal of neuroscience.

[17]  M. Hollenberg,et al.  Agonists of proteinase‐activated receptor‐2 affect transendothelial migration and apoptosis of human neutrophils , 2007, Experimental dermatology.

[18]  Huiyun Zhang,et al.  Modulation of mast cell proteinase‐activated receptor expression and IL‐4 release by IL‐12 , 2007, Immunology and cell biology.

[19]  David W. Johnson,et al.  Proinflammatory and proliferative responses of human proximal tubule cells to PAR-2 activation. , 2007, American journal of physiology. Renal physiology.

[20]  J. E. Lee,et al.  BMC Neuroscience BioMed Central , 2007 .

[21]  T. Bushell.  The emergence of proteinase‐activated receptor‐2 as a novel target for the treatment of inflammation‐related CNS disorders , 2007, The Journal of physiology.

[22]  H. Kergoat,et al.  RGC sensitivity to mild systemic hypoxia. , 2006, Investigative ophthalmology & visual science.

[23]  S. Gando,et al.  Differential Expression, Time Course and Distribution of Four PARs in Rats with Endotoxin-induced Acute Lung Injury , 2006, Inflammation.

[24]  A. Leger,et al.  Protease-Activated Receptors in Cardiovascular Diseases , 2006, Circulation.

[25]  W. Ferrell,et al.  Therapeutic Promise of Proteinase-Activated Receptor-2 Antagonism in Joint Inflammation , 2006, Journal of Pharmacology and Experimental Therapeutics.

[26]  Keisuke Kuida,et al.  Caspases 3 and 7: Key Mediators of Mitochondrial Events of Apoptosis , 2006, Science.

[27]  G. Reiser,et al.  Two types of protease-activated receptors (PAR-1 and PAR-2) mediate calcium signaling in rat retinal ganglion cells RGC-5 , 2005, Brain Research.

[28]  M. Hollenberg,et al.  Proteinase-Activated Receptor-2 Induction by Neuroinflammation Prevents Neuronal Death during HIV Infection1 , 2005, The Journal of Immunology.

[29]  Takeshi Hayashi,et al.  Deficiency of PAR-2 Gene Increases Acute Focal Ischemic Brain Injury , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[30]  S. Steinberg.  The Cardiovascular Actions of Protease-Activated Receptors , 2005, Molecular Pharmacology.

[31]  N. Bunnett,et al.  Protease-activated receptors: protease signaling in the gastrointestinal tract. , 2004, Current opinion in pharmacology.

[32]  J. A. Barnes,et al.  Protease activated receptors in cardiovascular function and disease , 2004, Molecular and Cellular Biochemistry.

[33]  A. Kawabata.  Gastrointestinal functions of proteinase-activated receptors. , 2003, Life sciences.

[34]  Thomas A. Luger,et al.  Proteinase-Activated Receptor-2 Mediates Itch: A Novel Pathway for Pruritus in Human Skin , 2003, The Journal of Neuroscience.

[35]  B. A. Sabel,et al.  Protease‐activated receptor subtype expression in developing eye and adult retina of the rat after optic nerve crush , 2003, Journal of neuroscience research.

[36]  R. Scarborough.  Protease-activated receptor-2 antagonists and agonists. , 2003, Current medicinal chemistry. Cardiovascular and hematological agents.

[37]  A. Kawabata.  PAR-2: structure, function and relevance to human diseases of the gastric mucosa , 2002, Expert Reviews in Molecular Medicine.

[38]  M. P. Murphy.  Pharmacogenomics: a critical component of patient stratification during drug development , 2002, Expert review of molecular diagnostics.

[39]  M. Krug,et al.  Four different types of protease‐activated receptors are widely expressed in the brain and are up‐regulated in hippocampus by severe ischemia , 2001, The European journal of neuroscience.

[40]  J. Moffatt,et al.  Protease-activated receptor-2 (PAR2) in the airways. , 2001, Pulmonary pharmacology & therapeutics.

[41]  T. Yorio,et al.  Characterization of a transformed rat retinal ganglion cell line. , 2001, Brain research. Molecular brain research.

[42]  Xiao-Ming Yin,et al.  Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways , 2000, Cell Research.

[43]  F. Medina,et al.  Strategies for cancer therapy using carcinoembryonic antigen vaccines , 2000, Expert Reviews in Molecular Medicine.

[44]  C. Napoli,et al.  Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  A. Kawabata,et al.  Protease-activated receptor (PAR), a novel family of G protein-coupled seven trans-membrane domain receptors: activation mechanisms and physiological roles. , 2000, Japanese journal of pharmacology.

[46]  N. Bunnett,et al.  Proteinase-activated receptors: a growing family of heptahelical receptors for thrombin, trypsin and tryptase. , 1999, Biochemical Society transactions.

[47]  J C Reed,et al.  Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. , 1998, Science.

[48]  R. Linsenmeier,et al.  Retinal hypoxia in long-term diabetic cats. , 1998, Investigative ophthalmology & visual science.

[49]  G. Evan,et al.  Apoptosis: Breaking the ICE , 1994, Current Biology.

[50]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[51]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[52]  Pournaras Cj,et al.  Occlusions vasculaires rétiniennes: les possibilités d'apport direct d'oxygène dans les territoires hypoxiques , 1985 .

[53]  A. Izzotti,et al.  Oxidative stress and glaucoma: injury in the anterior segment of the eye. , 2008, Progress in brain research.

[54]  G. Reiser,et al.  Proteinase-activated receptor-1 and -2 induce the release of chemokine GRO/CINC-1 from rat astrocytes via differential activation of JNK isoforms, evoking multiple protective pathways in brain. , 2007, The Biochemical journal.

[55]  L. Levin,et al.  Kinase-dependent differentiation of a retinal ganglion cell precursor. , 2006, Investigative ophthalmology & visual science.

[56]  N. Vergnolle,et al.  Proteinase-Activated Receptor-2 Induction by Neuroinflammation Prevents Neuronal Death during HIV Infection , 2005 .

[57]  Sudhir Gupta,et al.  Molecular signaling in death receptor and mitochondrial pathways of apoptosis (Review). , 2003, International journal of oncology.

[58]  C. Pournaras,et al.  [Retinal vascular occlusion: possibilities of a direct oxygen supply to the hypoxic areas]. , 1985, Klinische Monatsblatter fur Augenheilkunde.